Faith Davies, MD, MRCP, MRCPath, FRCPath is a professor of medicine and the director of the Phase I Clinical Trials program for both the Myeloma Institute and the Winthrop P. Rockefeller Cancer Institute at UAMS.
Dr. Davies is recognized internationally for her focus on innovative targeted molecular therapies and her expertise in the treatment of relapsed refracotry disease.
Dr. Davies earned her medical degree from the University of Wales College of Medicine and completed her general medical training in Cardiff and Birmingham. She completed her Haematology Specialist training in Leeds and London. Dr. Davies has focused for two decades on the biology and treatment of myeloma. Her focus has been on combining laboratory-based research on targeted approaches to myeloma therapy with clinical work involving the introduction of new drugs in the clinical setting, with an emphasis on Phase I, II and II clinical trials. Her research has examined potential new drugs and new genetic technologies and their applications in myeloma. Her lab work is aimed at identifying biologically based therapeutic targets in myeloma that are amenable to small molecule interventions and translating those findings into the clincical arena with a focus on individualized treatment.
Dr. Davies is a member of the British Society of Haemaology, the American Society of Hematology, the American Association for Cancer Research, the Royal College of Physicians, UK, and the Royal College of Pathologists, UK. She is widely published in leading peer-reviewed jourals and has contributed to a number of book chapters and reviews on myeloma biology and treatment. She is also a reviewer for a number of international journals and grants.
Videos from the Patient Power Network
Professional Certifications and Education
UAMS doctors treat a broad range of conditions some of which may not be listed below.